ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Stock split history for ImmunoPrecise Antibodies Ltd. (IPA)
ImmunoPrecise Antibodies Ltd. stock (symbol: IPA) underwent a total of 7 stock splits.
The most recent stock split occured on Nov 23, 2020.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2020-11-23 | 1:5 | 1 |
| 2017-01-03 | 1:3 | 1 |
| 2016-09-02 | 1:3 | 1 |
| 2013-05-30 | 4:1 | 4 |
| 2013-04-12 | 4:1 | 4 |
| 2011-10-14 | 1:10 | 1 |
| 2011-09-13 | 1:10 | 1 |